Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.
The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.
We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies – including GlaxoSmithKline, Pfizer, UCB, Merck, Bayer and Novartis.
News & Insights
News: 24 OCTOBER 2019
Allen & Overy hat die Sartorius AG (Sartorius), führender Partner der biopharmazeutischen Industrie und Forschung mit Sitz in Göttingen, bei der Finanzierung ihrer geplanten Übernahme von Teilen des Life-Science-Portfolios der Danaher Corporation, Washington, D.C. (Danaher), beraten.Lesen Sie mehr
Das sagen andere über uns
Strong European offering with noted expertise in IP and patent litigation matters. Well regarded for its impressive client portfolio, which spans the pharmaceutical, biotechechnology, medtech, diagnostics and healthcare industries. Also offers impressive expertise in commercial transactions and M&A.
Chambers Global 2018 (Life Sciences: Global-wide)
Fast and to-the-point advice and counselling... they have the understanding to adapt to what's needed.
Clients quoted in Chambers Europe 2017 (Life Sciences: Europe-wide)
The lawyers we worked with were uniformly excellent… it was great to work with a firm that had strong local counsel in several countries.
Client quoted in Chambers Europe 2017 (Intellectual Property: Europe-wide)
Life Sciences Hub
We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.View the blog
The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.Go to microsite
Growth Capital microsite
Allen & Overy is an engaged and active player in the growth company ecosystem.Go to microsite
According to UN estimates, the global cannabis market is currently worth approximately USD150 billion annually.Go to microsite
Download our sector brochure
An insight in to our Life Science and Healthcare sector 2020
Global trends in merger control enforcement
Record levels in the first half of 2018 and considerable contraction in the second.